TORONTO, Sept. 16 /CNW/ - In a head to head comparison of Interface
Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially
available heparin coated catheters, both products achieved significant
reductions (88%) in thrombus versus the polyurethane (Carbothane(TM)) control
(data on file).
"Due to the recent contamination, subsequent price increases, and safety
issues for Heparin, catheter manufacturers are seeking alternative coatings
for their products. Interface Biologics' Endexo(TM) anti-thrombic additives
are non-drug polymers that have anti platelet properties. These polymers are
compatible with a wide range of base polymers, and since they are an additive
rather than a coating, afford ease of process manufacturing as well as provide
both extra and intraluminal coverage, and are equivalent in thrombus reduction
performance to commercially available coatings," stated Rich Sullivan,
President and CEO of Interface Biologics.
The blood loop study was performed at the Medical Device Evaluation
Center (MDEC) in Salt Lake City Utah. "Catheters with effective Endexo
additives showed a significant reduction in thrombus versus a standard
polyurethane control, and were not statistically different in antithrombotic
efficacy versus a commercially available heparin coated catheter," stated
Sivaprasad Sukavaneshvar, Ph.D., VP of MDEC.
About Interface Biologics Inc.
Interface Biologics is a biomaterials company located in Toronto, Canada.
The company develops and manufactures novel anti-thrombic and anti-infective
polymers used in medical devices for cardiovascular and urological
For further information:
For further information: Mark Steedman, Director of Business
Development, firstname.lastname@example.org, (416) 673-8158